BiotechTube

OLAPARIB + PLACEBO

Phase 3Withdrawn
2 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Platinum Sensitive Relapsed Ovarian Cancer

Conditions

Platinum Sensitive Relapsed Ovarian Cancer

Trial Timeline

Jul 1, 2016 → Jun 1, 2019

NCT ID
NCT02392676

About OLAPARIB + PLACEBO

OLAPARIB + PLACEBO is a phase 3 stage product being developed by AstraZeneca for Platinum Sensitive Relapsed Ovarian Cancer. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02392676. Target conditions include Platinum Sensitive Relapsed Ovarian Cancer.

What happened to similar drugs?

0 of 6 similar drugs in Platinum Sensitive Relapsed Ovarian Cancer were approved

Approved (0) Terminated (1) Active (5)
🔄OLAPARIB + Single agent chemotherapyAstraZenecaPhase 3
🔄Olaparib 300mg tablets + Placebo to match olaparib 300mgAstraZenecaPhase 3
❌Nemvaleukin and Pembrolizumab Combination + Pembrolizumab + Nemvaleukin + Pegylated Liposomal Doxorubicin (PLD) + Paclitaxel + Topotecan + GemcitabineMerckPhase 3
🔄Rina-S + Paclitaxel + Topotecan + Pegylated liposomal doxorubicin (PLD) + GemcitabineGenmabPhase 3
🔄ZL-2306(nirapairb) + PlacebosZai LabPhase 3
🔄olvimulogene nanivacirepvec + Platinum chemotherapy: carboplatin (preferred) or cisplatin + Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin + Bevacizumab (or biosimilar)GeneluxPhase 3

Hype Score Breakdown

Clinical
17
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT02392676Phase 3Withdrawn
NCT02032823Phase 3Active

Competing Products

20 competing products in Platinum Sensitive Relapsed Ovarian Cancer

See all competitors
ProductCompanyStageHype Score
PRGN-3005 UltraCAR-T cells + PRGN-3005 UltraCAR-T cellsPrecigenPhase 1
27
OSI-906 + erlotinib + placeboAstellas PharmaPhase 2
35
ASP1650Astellas PharmaPhase 2
35
Niraparib + AnlotinibSun PharmaceuticalPhase 2
35
E7050 + CetuximabEisaiPhase 1/2
32
Farletuzumab + PlaceboEisaiPhase 2
35
PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd + PLD 40mg/m2 ivgtt q4wJiangsu Hengrui MedicinePhase 2
31
OLAPARIBAstraZenecaPhase 2
35
Batiraxcept + DurvalumabAstraZenecaPhase 1/2
24
cediranib and olaparibAstraZenecaPhase 2
35
Durvalumab and Tremelimumab + AZD1775 and carboplatin (CBPT) + AZD6738 and olaparibAstraZenecaPhase 2
35
olaparib+cediranib combination therapy + durvalumab + olaparib combination therapy + durvalumab + chemotherapy treatment + durvalumab + tremelimumab + chemotherapy treatment + durvalumab + tremelimumab + paclitaxel treatment + durvalumab +chemotherapy treatmentAstraZenecaPhase 2
31
ZD4054 Zibotentan + Paclitaxel + Carboplatin + PlaceboAstraZenecaPhase 2
27
OLAPARIB + Single agent chemotherapyAstraZenecaPhase 3
40
Olaparib 300mg tablets + Placebo to match olaparib 300mgAstraZenecaPhase 3
44
TILT-123 + pembrolizumab + pegylated liposomal doxorubicinMerckPhase 1/2
39
OSE2101 + Pembrolizumab 25 MG/ML [Keytruda]MerckPhase 2
39
Nemvaleukin and Pembrolizumab Combination + Pembrolizumab + Nemvaleukin + Pegylated Liposomal Doxorubicin (PLD) + Paclitaxel + Topotecan + GemcitabineMerckPhase 3
32
IBI363+IBI305Innovent BiologicsPhase 2
42
Nivolumab InjectionBristol Myers SquibbPhase 2
35